Recognition of phosphohistidine-containing peptides by antibodies
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
List view / Grid view
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
Researchers have published a step-by-step protocol on how to produce millions of mature human cells in a chimeric mouse embryo.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
Following a whole exome sequencing study, researchers have found that mutations in the SLITRK5 gene could be targeted by drugs to treat OCD.
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
In cell cultures, a compound named STM2457 was shown to interfere with coronavirus replication, making it a potential treatment for SARS-CoV-2.